Adiuvo Investment SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLADVIV00015
PLN
0.62
0.01 (1.96%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 8 Million ()

stock-summary
P/E

3.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.76

stock-summary
Return on Equity

-4.41%

stock-summary
Price to Book

-0.24

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Mar 2025)
Net Profit:
1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.57%
0%
-9.57%
6 Months
-22.0%
0%
-22.0%
1 Year
-39.42%
0%
-39.42%
2 Years
-34.18%
0%
-34.18%
3 Years
-30.67%
0%
-30.67%
4 Years
-78.26%
0%
-78.26%
5 Years
-88.53%
0%
-88.53%

Adiuvo Investment SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-9.83%
EBIT Growth (5y)
13.18%
EBIT to Interest (avg)
-9.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
-0.06
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
-0.27
EV to EBIT
-16.25
EV to EBITDA
-20.23
EV to Capital Employed
-4.55
EV to Sales
34.72
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 33.33% vs 200.00% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 125.00% vs -50.00% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "-2.40",
          "chgp": "120.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.90",
          "chgp": "11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.60",
          "val2": "-2.40",
          "chgp": "125.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "873.50%",
          "val2": "-8,026.20%",
          "chgp": "889.97%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -70.00% vs 400.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 77.27% vs 81.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "1.00",
          "chgp": "-70.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.20",
          "val2": "-5.10",
          "chgp": "37.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "2.80",
          "chgp": "-75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.10",
          "val2": "-1.20",
          "chgp": "-491.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-11.00",
          "chgp": "77.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,793.40%",
          "val2": "-5,194.90%",
          "chgp": "-459.85%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary

Mar'25
Mar'24
Change(%)
Net Sales
0.40
0.30
33.33%
Operating Profit (PBDIT) excl Other Income
0.50
-2.40
120.83%
Interest
1.00
0.90
11.11%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.60
-2.40
125.00%
Operating Profit Margin (Excl OI)
873.50%
-8,026.20%
889.97%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2025 is 33.33% vs 200.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 125.00% vs -50.00% in Mar 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
0.30
1.00
-70.00%
Operating Profit (PBDIT) excl Other Income
-3.20
-5.10
37.25%
Interest
0.70
2.80
-75.00%
Exceptional Items
-7.10
-1.20
-491.67%
Consolidate Net Profit
-2.50
-11.00
77.27%
Operating Profit Margin (Excl OI)
-9,793.40%
-5,194.90%
-459.85%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -70.00% vs 400.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 77.27% vs 81.00% in Dec 2023

stock-summaryCompany CV
About Adiuvo Investment SA stock-summary
stock-summary
Adiuvo Investment SA
Pharmaceuticals & Biotechnology
Adiuvo Investments SA is a Poland-based company engaged in the financial industry. The Company focuses on the selection, development, financing and commercialization of biomedical projects on the international market. By providing intellectual property protection, technology validation in clinical trials and obtaining certificates allowing products to market, Adiuvo Investments SA is able to commercialize projects in diverse business model and internationally. The Company is looking for and invests in projects in the segments of the nutraceutical, medical devices and the digital health. Its business portfolio encompasses Airway Medix, Algae Labs, Carocelle, Cambridge Chocolate Technology, Endomedical, Esthechoc, Glia, Joint Polish Investment Fund, Marmar Investment, Nanoxide and Peptaderm.
Company Coordinates stock-summary
Company Details
Ul. Gen. Jozefa Zajaczka 11/14 , WARSZAWA None : 01-510
stock-summary
Tel: 48 22 408448048 22 4909401
stock-summary
Registrar Details